The role of in vitro-in vivo correlation in product development and life cycle management

Pharmaceutical Product Development: In Vitro-In Vivo Correlation

Volumn , Issue , 2007, Pages 71-105

  Li, Shoufeng ^a   Mueller Zsigmondy, Martin ^a   Yin, Hequn ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 76249130433     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (72)

1. Venkatesh S, Lipper RA. Role of the development scientist in compound lead selection and optimization. J Pharm Sci 2000; 89:145-154.
2. Lipper RA. How can we optimize selection of drug development candidates from many compounds at the discovery stage? Mod Drug Discov 1999; (Jan/Feb):55-60.
3. Li S, He H, Parthiban LJ, Yin H, Serajuddin ATM. IV-IVC considerations in the development of immediate-release oral dosage form. J Pharm Sci 2005; 94(7):1397-1417.
4. Center for Drug Evaluation and Research (CDER). Guidance for industry: Extended Release Oral Dosage Forms: Development, Evaluation, And Application of In Vitro/ In Vivo Correlation. Rockville, MD: US Department of Health and Human Services, 1997.
5. Young D. In vitro in vivo correlation of controlled release parenterals, AAPS Meeting, Baltimore, MD, 2003.
6. Note for guidance on quality of modified release products: A: Oral Dosage Forms, B. Transdermal Dosage Forms, Section I (Quality). The European Agency for the Evaluation of Medicinal Products, Human Medicines Evaluation Unit (EMEA), London, 1999.
7. Food and Drug Administration, Center for Drug Evaluation (CDER). Guidance for industry: Modified Release Solid Oral Dosage Forms: Scale-up and Postapproval Changes: Chemistry, Manufacture and Controls, In Vitro Dissolution Testing and In Vivo Bioequivalence Documentation. September 1997.
8. Mahayni H, Rekhi GS, Uppoor RS. Evaluation of external predictability of an in vitro-in vivo correlation for an extended-release formulation containing metoprolol tartrate. J Pharm Sci 2000; 89(10):1354-1361.
9. United States Pharmacopeia XXVIII, General Information: In Vitro and In Vivo Evaluation of Dosage Forms. Ch. 1088, 2005.
10. Turner S, Federici C, Hite M, et al. Formulation development and human in vitro-in vivi correlation for a novel, monolithic controlled-release matrix system of high load and highly water-soluble drug niacin. Drug Dev Ind Pharm 2004; 30(8):797-807.
11. Brockmeier D. In vitro/in vivo correlation of dissolution using moments of dissolution and transit times. Acta Pharm Technolo 1986; 32(4):164-174.
12. Podczeck F. Comparison of in vitro dissolution profiles by calculating mean dissolution time (MDT) or mean residence time (MRT). Int J Pharm 1993; 97:93-100.
13. Lake OA, Olling M, Barends DM. In vitro/in vivo correlations of dissolution data of carbamazepine immediate release tablets with pharmacokinetic data obtained in healthy volunteers. Eur J Pharm Biopharm 1999; 48:13-19.
14. Abrahamsson B, Lennernäs H. Application of the biopharmaceutic classification system now and in the future. In: van de Waterbeemd H, Lennernäs H, Artursson P, eds. Drug Bioavailability, 1st ed. Weinheim: Wiley-VCH, 2003:495-531.
15. Drewe J, Guitard P. In vitro-in vivo correlation for modified formulations. J Pharm Sci 1993; 82(2):132-137.
16. Tashtouch BM, Al-Qashi ZS, Najib NM. In vitro and in vivo evaluation of glibenclamide in solid dispersion systems. Drug Dev Ind Pharm 2004; 30(6):601-607.
17. Posti J, Katila K, Kostiainen T. Dissolution rate limited bioavailability of flutamide, and in vitro-in vivo correlation. Eur J Pharm Biopharm 2000; 49:35-39.
18. Vaughan DP, Leach RH. Simple transformation method for predicting plasma drug profiles from dissolution rates. J Pharm Sci 1976; 65(4):601-603.
19. Shepard T, Hayes S, Farrell C. Development of a level A IVIVC for a BCS Class 2 IR product. http://www.globomaxservice.com/resource/AAPS2003_DevelLevelA.pdf (accessed August 2005).
20. Kortejaervi H, Mikkola J, Baeckman M, Antila S, Marvola M. Development of level A, B and C in vitro-in vivo correlations for modified-release levosimendan capsules. Int J Pharm 2002; 241(1):87-95.
21. Akikmoto M, Furuya A, Nakamura M. Release and absorption characteristics of chlorphenesin carbamate sustained-release formulations: in vitro-in vivo and in vivo dog-humen correlations. Int J Pharm 1995; 117:31-39.
22. Rao BS, Seshasayana A, Saradhi SVP. Correlation of in vitro release and in vivo absorption characteritics of rifampicin from ethylcellulose coated nonpareil beads. Int J Pharm 2001; 230:1-9.
23. Langenbucher F. Handling of computational in vitro/in vivo correlation problems by Microsoft Excel II. Principles and some general algorithms. Eur J Pharm Biopharm 2002; 53:1-7.
24. Wagner JG. Application of the Loo-Riegelman absorption method. J Pharmacokin Biopharm 1975; 3(1):51-67.
25. Frick A, Möller H, Wirbitzky E. Biopharmaceutical characterization of oral controlled/modified-release drug Products. In vitro/in vivo correlation of roxatidine. Eur J Pharm Biopharm 1998; 46:313-319.
26. Langenbucher F. Numerical convolution/deconvolution as a tool for correlating in vitro with in vivo drug availability. Pharm Ind 1982; 44:1166-1172.
27. Gibaldi M, Perrier D. Pharmacokinetics. 2nd ed. New York: Marcel Dekker, 1982.
28. Shargel L, Yu ABC. Applied Biopharmaceutics & Pharmacokinetics. 4th ed. East Norwalk, CT: Appleton-Century-Crofts, 1999.
29. Humbert H, Cabiac MD, Bosshardt H. In vitro-in vivo correlation of a modified-release oral form of ketotifen: in vitro dissolution rate specification. J Pharm Sci 1994; 83(2):131-136.
30. Langenbucher F. Handling of computational in vitro/in vivo correlation problems by Microsoft Excel: III. Convolution and deconvolution. Eur J PharmBiopharm 2003; 56(3):429-437.
31. Langenbucher F. Handling of computational in vitro/in vivo correlation problems by Microsoft Excel: IV. Generalized matrix analysis of linear compartment systems. Eur J Pharm Biopharm 2005; 59(1):229-235.
32. Buchwald P. Direct, differential-equation-based in vitro-in vivo correlation (IVIVC) method. J Pharm Pharmacol 2003; 55(4):495-504.
33. Gillespie WR. Convolution-based approaches for in vivo-in vitro correlation modeling. In: Young D, Devane JG, Butler J. eds. In Vitro-In Vivo Correlations. New York: Plenum. Adv Exp Med Biol 1997; 423:53-65.
34. Gomeni R, Angeli C, Bye A. In silico prediction of optimal in vivo delivery properties using convolution-based model and clinical trial simulation. Pharm Res 2002; 19(1):99-103.
35. Nicolaides E, Symillides M, Dressman JB. Biorelevant dissolution testing to predict the plasma profile of lipophilic drugs after oral administration. Pharm Res 2001; 18(3):380-388.
36. Polli JE, Rekhi GS, Augsburger LL, et al. Methods to compare dissolution profiles and a rationale for wide dissolution specifications for metoprolol tartrate tablets. J Pharm Sci 1997; 86(6):690-700.
37. Shepard T, Farrell C. The incorporation of time-scaling in ivivc models to account for apparent non-linear relationships, http://www.globomaxservice.com/resource/M1226.pdf (accessed August 2005).
38. Shepard T, Rochdi M. development and validation of a time scaled in vitro/in vivo correlation for isosorbide-5-mononitrate controlled release geomatrix formulations, http://www.globomaxservice.com/resource/M1350_final.pdf (accessed August 2005).
39. Drewe J, Guitard P. In vitro-in vivo correlation for modified formulations. J Pharm Sci 1993; 82(2):132-137.
40. Liu Y, Schwartz JB, Schnaare RL, et al. A multi-mechanistic drug release approach in a bead dosage form and in vivo predictions. Pharm Dev Technol 2003; 8(4):409-417.
41. Huang Y-B, Tsai Y-H, Yang W-C, et al. Once-daily propranolol extended-release tablet dosage form: formulation design and in vitro/in vivo investigation. Eur J Pharm Biopharm 2004; 58:607-614.
42. Corrigan OI, Devlin Y, Butler J. Influence of dissolution medium buffer composition on ketoprofen release from ER products and in vitro-in vivo correlation. Int J Pharm 2003; 254(2):147-154.
43. Takka S, Sakr A, Goldberg A. Development and validation of an in vitro-in vivo correlation for buspirone hydrochloride extended release tablets. J Control Release 2003; 88:147-157.
44. Qiu Y, Garren J, Samara E, et al. Once-a-day controlled-release dosage form of Divalproex Sodium II: development of a predictive in vitro drug release method. J Pharm Sci 2003; 92(11):2317-2325.
45. Polli JE, Crison JR, Amidon GL. Novel approach to the analysis of in vitro-in vivo relationships. J Pharm Sci 1996; 85:753-760.
46. Dunne A, O'Hara T, DeVane J. Level A in vivo-in vitro correlation: nonlinear models and statistical methodology. J Pharm Sci 1997; 86(11):1245-1249.
47. Lipinski CA. Computational alerts for potential absorption problems: profiles of clinically tested drugs. Tools for oral absorption. Part Two. Predicting human absorption. Biotech, PDD symposium, AAPS, Miami, 1995.
48. Palm K, Luthman K, Ungell AL, Strandlund G, Artursson P. Correlation of drug absorption with molecular surface properties. J Pharm Sci 1996; 85(1):32-39.
49. Perez MA, Sanz MB, Torres LR, Avalos RG, Gonzalez MP, Diaz HG. A topological sub-structural approach for predicting human intestinal absorption of drugs. Eur J Med Chem 2004; 39(11):905-916.
50. Hall LH, Hall LM. QSAR modeling based on structure-information for properties of interest in human health. SAR QSAR Environ Res 2005; 16(1-2):13-41.
51. Bai JPF, Utis A, Crippen G, et al. Use of classification regress tree in predicting oral absorption in humans. J Chem Inf Comput Sci 2004; 44:2061-2069.
52. Obata K, Sugano K, Saitoh R, et al. Prediction of oral drug absorption in humans by theoretical passive absorption model. Int J Pharm 2005; 293(1-2):183-192.
53. Wolohan PR, Clark RD. Predicting drug pharmacokinetic properties using molecular interaction fields and SIMCA. J Comput Aided Mol Des 2003; 17(1):65-76.
54. Yu LX, Crison Jr, Amidon GL. Compartmental transit and dispersion model analysis of small intetinal transit flow in humans. Int J Pharm 1996; 140:111-118.
55. Parrot N, Lave T. Prediction of intestinal absorption: comparative assessment of GASTROPLUS and IDEA. Eur J Pharm Sci 2002; 17:51-61.
56. Horter D, Dressman JB. Influence of physicochemical properties on dissolution of drugs in the gastro-intestinal tract. Adv Drug Deliv Rev 2001; 46:75-87.
57. Ozturk SS, Palsson BO, Dressman JB. Dissolution of ionizable drugs in buffered and unbuffered solutions. Pharm Res 1988; 5:272-282.
58. Mooney KG, Mintun MA, Himmelstein KJ, Stella VJ. Dissolution kinetics of carboxylic acids I: effect of pH under unbuffered conditions. J Pharm Sci 1981; 70:13-22.
59. Serajuddin ATM, Jarowski C. Effect of diffusion layer pH and solubility on the dissolution rate of pharmaceutical acids and sodium salts II: salicylic acid, theophylline, and benzoic acid. J Pharm Sci 1985; 74:148-154.
60. Morris KR, Fakes MG, Thakur AB, et al. Integrated approach to the selection of optimal salt form for a new drug candidate. Int J Pharm 1994; 105:209-217.
61. Anderson BD, Flora KP. Preparation of water-soluble compounds through salt formation. In: Wermuth CG, ed. The Practice of Medicinal Chemistry. London: Academic Press, 1996:739-754.
62. Gould PL. Salt selection for basic drugs. Int J Pharm 1986; 33:201-217.
63. Berge SM, Bighley LD, Monkhouse DC. Pharmaceutical salts. J Pharm Sci 1977; 66:1-19.
64. Nelson E. Solution rate of theophylline salts and effects from oral administration. J Am Pharm Assoc Sci Educ 1957; 46:607.
65. Serajuddin ATM, Jarowski CI. Effect of diffusion layer pH and solubility on the dissolution rate of pharmaceutical bases and their hydrochloride salts. Part 1. Phenazo-pyridine. J Pharm Sci 1985; 74:142-147.
66. Schettler T, Paris S, Pellett M, Kidner S, Wilkinson D. Comparative pharmacokinetics of two fast-dissolving oral ibuprofen formulations and a regular release ibuprofen tablet in healthy volunteers. Clin Drug Invest 2001; 21(Jan): 73-78.
67. Johnson KC, Swindell AC. Guidance in the setting of drug particle size specifications to minimize variability in absorption. Pharm Res 1996; 13:1795-1798.
68. Food and Drug Administration, Center for Drug Evaluation (CDER), Rockville, MD. Guidance for industry, waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system, August 2000.
69. Fassen F, Vromans H. Biowaivers for oral immediate-release products. Clin Pharmacokinet 2004; 43(15):1117-1126.
70. Verbeek RK, Junginger HE, Midha KK. Biowaiver monographs for immediate release solid oral dosage forms based on biopharmaceutics classification system (BCS) literature data: chloroquine phosphate, chloroquine sulfate, and chloroquine hydrochloride. J Pharm Sci 2005; 94(7):1389-1395.
71. Veng-Pedersen P, Gobburu JV, Meyer MC, Straughn AB. Carbamazepine level-A in vivo in vitro correlation (IVIVC): scaled convolution based predictive approach. Biopharm Drug Dispos 2000; 21(1):1-6.
72. Sunesen VH, Pedersen BL, Kristensen HG, Muellertz A. In vivo in vitro correlations for a poorly soluble drug, danazol, using the flow-through dissolution method with biorelevant dissolution media. Eur J Pharm Sci 2005; 24(4):305-313.